Safety and Immunogenicity of MVA85A Prime and Bacille Calmette-Guerin Boost Vaccination

PHASE2CompletedINTERVENTIONAL
Enrollment

248

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions
TuberculosisHIV
Interventions
BIOLOGICAL

MVA85A

BIOLOGICAL

Candin

BIOLOGICAL

BCG Vaccine SSI

"All infants who test negative by HIV PCR will receive BCG vaccination at 8 weeks of age.~Infants who test positive by HIV PCR will not receive BCG vaccination."

Trial Locations (2)

Unknown

Desmond Tutu TB Centre (DTTC), Stellenbosch University, Khayelitsha

South African Tuberculosis Vaccine Initiative (SATVI), University of Cape Town, Worcester

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Medical Research Council

OTHER_GOV

collaborator

Wellcome Trust

OTHER

collaborator

Department for International Development, United Kingdom

OTHER_GOV

collaborator

University of Oxford

OTHER

collaborator

University of Stellenbosch

OTHER

collaborator

Oxford-Emergent Tuberculosis Consortium

UNKNOWN

lead

Mark Hatherill

OTHER